Targeting the NR3C1‐ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer
Jing Yang, Puyuan Chen, Yawen Zheng, Feiyue Shi, Min Wang, Luwei Xu, Xiaowei Wei, Xiumei Wang · 2026
Read Targeting the NR3C1‐ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer by Jing Yang, Puyuan Chen, Yawen Zheng, Feiyue Shi, Min Wang, Luwei Xu, Xiaowei Wei, Xiumei Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13395388.txt.
Description
Jing Yang and co-authors find, in 2026, a gene axis that helps prostate cancer shrug off radiation. A hormone receiver named NR3C1 ran high in resistant tumours and tracked with poor outlook. It switches on an enzyme, ACSL4, that loads fats into cell skins. Those fats can either feed growth or, under the right push, rust and kill the cell.
A plant-derived drug, dihydroartemisinin, gave that push. With ACSL4 high, the drug sparked ferroptosis, a rust-like cell death, and made radiation work again in cells and mouse tumours. A blocker of that death path undid the gain. The authors back ACSL4 as a marker for the paired cure.
Catalog record
| CREATOR | Jing Yang, Puyuan Chen, Yawen Zheng, Feiyue Shi, Min Wang, Luwei Xu, Xiaowei Wei, Xiumei Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48145 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |